All In Biotech

Free tool

FAERS Monitor: Kimyrsa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214155 or its brand name (Kimyrsa, Oritavancin Diphosphate). Reports on generic versions are filed under their own applications.

Reports

297

Serious

98

33% of reports

Hospitalization

30

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • multiple use of single-use product109
  • chills92
  • infusion related reaction67
  • off label use49
  • back pain42
  • dyspnoea38
  • pruritus37
  • tremor36
  • flushing35
  • nausea35
  • rash25
  • chest pain24
  • vomiting23
  • erythema17
  • feeling cold17

Reports by year received

View as table
YearReports
20181
20201
20212
202252
2023144
202453
202535
20269

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,862 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
multiple use of single-use productSignal1091402.11204.8148,317
infusion related reactionSignal6771.758.04,607
chillsSignal9255.646.94,903
feeling coldSignal1743.327.3661
flushingSignal3524.417.9765
tremorSignal3615.411.3473
back painSignal4212.89.7450
chest painSignal249.26.3168
pruritusSignal376.85.0181
erythemaSignal175.93.764
dyspnoeaSignal384.83.5112
rashSignal254.12.856
off label useSignal494.03.1110
vomitingSignal233.52.339
nauseaSignal353.12.351

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.